Protocol Ledger

NCT05304481 · Phase II · RECRUITING

Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma

Interventional Phase II clinical trial protocol NCT05304481 sponsored by Lukas Biomedical in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-14 Enrollment: 95 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05304481
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)95 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05304481
Protocol FieldVerified Registry Value
NCT IdentifierNCT05304481
Consolidated Lead SponsorLukas Biomedical
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment95 participants (ESTIMATED)
Registered Start Date2022-05-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI